Overview
CADPT03A12001 is a prospective, multi-center study that is designed to follow all enrolled patients who have received treatment with OTQ923 for long-term safety and efficacy.
Description
This study is monitoring patients treated with OTQ923, an investigational drug product of ex vivo genome-edited autologous hematopoietic stem and progenitor cells (HSPCs) that induces fetal hemoglobin (HbF) production, for a total of 15 years following infusion to monitor long-term safety and efficacy.
Eligibility
Inclusion Criteria:
- Accepted invitation to join based on prior treatment with gene therapy.
- Patients must provide informed consent prior to their entry into this study.
Exclusion Criteria:
- Completion of less than 1 year of safety follow-up in the treatment protocol (CADPT03A12101)